Gerresheimer AG (ETR:GXI) has been given a €78.00 ($91.76) price objective by investment analysts at Independent Research GmbH in a research report issued on Wednesday, July 19th. The firm currently has a “neutral” rating on the stock.

A number of other brokerages have also recently issued reports on GXI. Hauck & Aufhaeuser set a €80.00 ($94.12) price objective on shares of Gerresheimer AG and gave the company a “neutral” rating in a research note on Friday, July 14th. Deutsche Bank AG set a €82.00 ($96.47) price objective on shares of Gerresheimer AG and gave the company a “buy” rating in a research note on Friday, July 14th. Goldman Sachs Group, Inc. (The) set a €73.00 ($85.88) price objective on shares of Gerresheimer AG and gave the company a “neutral” rating in a research note on Friday, July 14th. Kepler Capital Markets set a €70.00 ($82.35) price objective on shares of Gerresheimer AG and gave the company a “sell” rating in a research note on Thursday, July 13th. Finally, Commerzbank Ag set a €73.00 ($85.88) price objective on shares of Gerresheimer AG and gave the company a “neutral” rating in a research note on Thursday, July 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of €79.80 ($93.88).

Shares of Gerresheimer AG (ETR:GXI) traded up 1.58% during midday trading on Wednesday, hitting €69.39. The stock had a trading volume of 60 shares. The stock has a 50-day moving average of €69.98 and a 200 day moving average of €72.84. The stock has a market cap of €2.18 billion and a PE ratio of 19.22. Gerresheimer AG has a 52 week low of €64.00 and a 52 week high of €79.47.

TRADEMARK VIOLATION NOTICE: “Gerresheimer AG (GXI) Given a €78.00 Price Target at Independent Research GmbH” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/14/gerresheimer-ag-gxi-given-a-78-00-price-target-by-independent-research-gmbh-analysts-updated-updated-updated.html.

Gerresheimer AG Company Profile

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Analyst Recommendations for Gerresheimer AG (ETR:GXI)

Receive News & Stock Ratings for Gerresheimer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer AG and related stocks with our FREE daily email newsletter.